ASCO: Daraxonrasib Effective for Metastatic Pancreatic Ductal Adenocarcinoma

MONDAY, June 1, 2026 -- Daraxonrasib is effective for patients with RAS-mutant and other metastatic pancreatic ductal adenocarcinomas (mPDACs), according to a study presented at the annual meeting of the American Society of Clinical Oncology, held...